Active, not recruitingPhase 3NCT04629248
A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy
Studying Primary membranous glomerulonephritis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Hoffmann-La Roche
- Principal Investigator
- Clinical TrialsHoffmann-La Roche
- Intervention
- Obinutuzumab(drug)
- Enrollment
- 142 target
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2021 – 2027
Study locations (30)
- Kaiser Permanente - San Francisco Medical Center, San Francisco, California, United States
- University of Colorado in Denver-Anschutz Medical Campus, Aurora, Colorado, United States
- Accel Research Sites; Mid-Florida Kidney and Hypertension Care, Altamonte Springs, Florida, United States
- University of Iowa, Iowa City, Iowa, United States
- Henry Ford Hospital, Detroit, Michigan, United States
- Mayo Clinic, Rochester, Minnesota, United States
- Columbia University Medical Center, New York, New York, United States
- Nephrotex Research Group, Dallas, Texas, United States
- Organizacion Medica de Investigacion, Buenos Aires, Argentina
- CINME, Buenos Aires, Argentina
- Hospital Britanico Buenos Aires, Buenos Aires, Argentina
- Ser Servicos Especializados Em Reumatologia, Salvador, Estado de Bahia, Brazil
- Hospital de Base de Sao Jose do Rio Preto, São José do Rio Preto, São Paulo, Brazil
- Hospital do Rim e Hipertensão - Fundação Oswaldo Ramos, São Paulo, São Paulo, Brazil
- Hospital das Clinicas - FMUSP, São Paulo, São Paulo, Brazil
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04629248 on ClinicalTrials.govOther trials for Primary membranous glomerulonephritis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07289763Phase II Randomized, Open-label, Multicenter Clinical Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of SHR-2173 Injection in Patients With Primary Membranous NephropathyGuangdong Hengrui Pharmaceutical Co., Ltd
- RECRUITINGPHASE2, PHASE3NCT07204275A Study to Evaluate Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)Vertex Pharmaceuticals Incorporated
- RECRUITINGPHASE2NCT07157787Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)Alexion Pharmaceuticals, Inc.
- RECRUITINGPHASE2NCT07096843A Phase 2 Study of Budoprutug in Subjects With Primary Membranous NephropathyClimb Bio, Inc.
- RECRUITINGPHASE3NCT06962800A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)Biogen
- RECRUITINGPHASE1NCT06982729Study of YK012 in Primary Membranous NephropathyExcyte Biopharma Ltd
- RECRUITINGNCT06242327An Outcome Analysis of Primary Membranous NephropathyMario Negri Institute for Pharmacological Research
- ACTIVE NOT RECRUITINGPHASE2NCT06642909A Phase II Study of Zuberitamab Injection in Patients With Primary Membranous NephropathyBioRay Pharmaceutical Co., Ltd.